Raymond Prudo-Chlebosz - Mar 20, 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role: Director
Signature: /s/ Torsten Hombeck, as Attorney-in-Fact
Stock symbol: AKTX
Transactions as of: Mar 20, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/24/2025, 05:00 PM
Previous filing: Mar 10, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKTX	American Depositary Shares representing Ordinary Shares						2.48M	Mar 20, 2025	Direct	F1
holding	AKTX	American Depositary Shares representing Ordinary Shares						19.4K	Mar 20, 2025	Praxis Trustees Limited	F1
holding	AKTX	American Depositary Shares representing Ordinary Shares						400K	Mar 20, 2025	RPC Pharma Limited	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKTX	Stock Option (Right to Buy)	Award	$0	+175K		$0.00	175K	Mar 20, 2025	American Depositary Shares representing Ordinary Shares	175K	$1.50	Direct	F1, F2
transaction	AKTX	Stock Option (Right to Buy)	Award	$0	+225K		$0.00	225K	Mar 20, 2025	American Depositary Shares representing Ordinary Shares	225K	$1.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2	The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer.
F3	The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter.